|
|||||
|
|
5-HT1A receptor ligands and their therapeutic applications: review of new patents |
|
| Authors: | Jakub Staroń Ryszard Bugno Adam S. Hogendorf Andrzej J. Bojarski |
| Affiliation: | Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland |
| Abstract: | Introduction: 5-HT1AR was one of the first discovered serotonin receptors and is one of the most thoroughly studied. Dysfunctions associated with 5-HT1AR neurotransmission are linked to several psychiatric disorders, including anxiety, depression, and movement disorders. Areas covered: The current review covers patent literature published between January 2012 and May 2018. Queries were performed on Espacenet, SciFinder, clinicaltrials.gov, pharmacodia.com, and the websites of pharmaceutical companies. Expert opinion: Several novel therapeutic applications have been proposed for 5-HT1AR ligands, i.e. prostate cancer treatment, gastrointestinal and cardiopulmonary disorders, facilitation of urination and defecation, and L-DOPA-induced dyskinesia. Interestingly, no patent application has been filed by big pharma companies, while numerous researches are being conducted in smaller companies and academia. |
| Keywords: | 5-HT1A agonist antagonist serotonin receptor serotonin modulator therapeutic patent |